Q32 Bio is a clinical-stage biotechnology company developing biologics designed to restore healthy immune balance, with lead candidate bempikibart aimed at severe and very severe alopecia areata. Because the company is pre-revenue in any meaningful commercial sense, its stock price target depends almost entirely on clinical progress and the estimated size of its addressable market rather than near-term earnings.
Seven current, attributable analyst price targets were reviewed: Leerink Partners at $40 (reiterated November 5, 2026), Oppenheimer at $40 (November 5, 2026), Morgan Stanley at $34 (November 5, 2026), Wells Fargo at $59 (November 5, 2026), H.C. Wainwright at $36 (November 4, 2026), Clear Street at $38, and Jefferies at $29. That produces a mean of roughly $39.43, rounded to a $40 central target, with a range of $29 to $59. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The wide spread reflects a common pattern in biotech coverage: bullish analysts model bempikibart as a potential blockbuster in an underserved severe alopecia areata population, while more cautious analysts discount for execution and regulatory risk. The consensus is uniformly constructive — no Hold or Sell ratings appear among the current targets — but the $30 gap between the low and high estimates signals genuine uncertainty about the size of the opportunity.
With the stock near $8.72, moving to $40 requires upside of about 359%, a very large move by any standard. The shares have already been extraordinarily volatile, trading within a 52-week range of roughly $1.90 to $23.57. Notably, the $40 target sits well above the 52-week high, meaning the market would need to assign meaningfully more value than it has at any point in the past year.
The path would most likely run through continued positive readouts from the bempikibart program, successful regulatory filings, and eventual commercialization. In its most recent quarterly report, the company posted a narrower-than-expected loss per share, and H.C. Wainwright raised its target after what it described as positive week 36 data — a key catalyst that helped lift the stock from the low single digits.
The stock's 52-week range of roughly $1.90 to $23.57 frames its recent behavior. After trading near the lows, the shares have recovered to the high single digits, but the prior high near $23.57 remains a meaningful technical hurdle well below the $40 target. A sustained move toward $40 would require clearing that prior high and establishing new territory, so investors may view the $23–$24 zone as an important resistance area and the single-digit range as a key support level on pullbacks. From what I see, reviewing patterns with available tools helps put these levels in perspective.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. For Q32 Bio, the most important items to watch are bempikibart clinical data readouts, regulatory interactions with the FDA, quarterly cash position and burn rate, and any analyst target revisions that follow new data. Because the company is pre-revenue, trial milestones — not earnings beats — are likely to be the dominant driver of whether the shares can move toward the $40 level.
The $40 central target for Q32 Bio — the mean of seven verified analyst targets ranging from $29 to $59 — represents an aspiration anchored in bempikibart's blockbuster potential rather than current fundamentals. Reaching it would require a roughly 359% advance and a market re-rating well beyond the stock's 52-week high, making it a very large move. The Strong Buy consensus and positive recent data support the bullish case, while clinical-stage risk, cash needs, and competition from approved therapies remain substantial obstacles. The wide analyst range underscores genuine uncertainty. Investors should monitor clinical readouts and cash position above all, with no guarantee the target will be reached.
I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking how market conditions and technical factors evolve for names like this one. The system monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals, which can complement fundamental work when reviewing entry points or watching for shifts in momentum. It has become a regular part of how I cross-check ideas without replacing core research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
QTTB's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In 165 of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTTB as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 50-day moving average for QTTB moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.600) is normal, around the industry mean (3.592). P/E Ratio (2.946) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology